Clarity Pharmaceuticals Ltd (CU6) - Net Assets

Latest as of June 2025: AU$90.23 Million AUD ≈ $63.84 Million USD

Based on the latest financial reports, Clarity Pharmaceuticals Ltd (CU6) has net assets worth AU$90.23 Million AUD (≈ $63.84 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$101.17 Million ≈ $71.59 Million USD) and total liabilities (AU$10.94 Million ≈ $7.74 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CU6 financial resilience to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets AU$90.23 Million
% of Total Assets 89.19%
Annual Growth Rate 73.2%
5-Year Change 344.98%
10-Year Change N/A
Growth Volatility 162.67

Clarity Pharmaceuticals Ltd - Net Assets Trend (2018–2025)

This chart illustrates how Clarity Pharmaceuticals Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Clarity Pharmaceuticals Ltd balance sheet assets for the complete picture of this company's asset base.

Annual Net Assets for Clarity Pharmaceuticals Ltd (2018–2025)

The table below shows the annual net assets of Clarity Pharmaceuticals Ltd from 2018 to 2025. For live valuation and market cap data, see Clarity Pharmaceuticals Ltd market cap and net worth.

Year Net Assets Change
2025-06-30 AU$90.23 Million
≈ $63.84 Million		 -38.32%
2024-06-30 AU$146.30 Million
≈ $103.51 Million		 +111.49%
2023-06-30 AU$69.18 Million
≈ $48.95 Million		 -25.00%
2022-06-30 AU$92.24 Million
≈ $65.26 Million		 +354.87%
2021-06-30 AU$20.28 Million
≈ $14.35 Million		 +148.53%
2020-06-30 AU$8.16 Million
≈ $5.77 Million		 -11.57%
2019-06-30 AU$9.23 Million
≈ $6.53 Million		 +378.17%
2018-06-30 AU$1.93 Million
≈ $1.37 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Clarity Pharmaceuticals Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 16876674200.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (June 2025)

Component Amount Percentage
Common Stock AU$255.89 Million 283.59%
Other Comprehensive Income AU$11.34 Million 12.57%
Total Equity AU$90.23 Million 100.00%

Clarity Pharmaceuticals Ltd Competitors by Market Cap

The table below lists competitors of Clarity Pharmaceuticals Ltd ranked by their market capitalization.

Company Market Cap
Jiangsu Canlon Building Materials Co Ltd
SHE:300715
 $763.44 Million
Suntront Tech
SHE:300259
 $763.46 Million
Hefei Department Store Group Co Ltd
SHE:000417
 $763.47 Million
Dongguan Golden Sun Abrasives Co Ltd
SHE:300606
 $763.63 Million
Puyang Refractories Group Co Ltd
SHE:002225
 $763.35 Million
AVALON TECHNOLOGIES LTD
NSE:AVALON
 $763.31 Million
Yunnan Yunwei Co Ltd Class A
SHG:600725
 $762.88 Million
PHARMING GRP SP. ADRS
F:PHG
 $762.66 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Clarity Pharmaceuticals Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 146,297,450 to 90,230,512, a change of -56,066,938 (-38.3%).
  • Net loss of 64,295,435 reduced equity.
  • Share repurchases of 193,386 reduced equity.
  • New share issuances of 2,404,534 increased equity.
  • Other comprehensive income increased equity by 1,790,270.
  • Other factors increased equity by 4,227,079.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income AU$-64.30 Million -71.26%
Share Repurchases AU$193.39K -0.21%
Share Issuances AU$2.40 Million +2.66%
Other Comprehensive Income AU$1.79 Million +1.98%
Other Changes AU$4.23 Million +4.68%
Total Change AU$- -38.32%

Book Value vs Market Value Analysis

This analysis compares Clarity Pharmaceuticals Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 10.26x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 386.18x to 10.26x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2018-06-30 AU$0.01 AU$2.90 x
2019-06-30 AU$0.04 AU$2.90 x
2020-06-30 AU$0.03 AU$2.90 x
2021-06-30 AU$0.08 AU$2.90 x
2022-06-30 AU$0.37 AU$2.90 x
2023-06-30 AU$0.27 AU$2.90 x
2024-06-30 AU$0.54 AU$2.90 x
2025-06-30 AU$0.28 AU$2.90 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Clarity Pharmaceuticals Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -71.26%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -679.45%
  • • Asset Turnover: 0.09x
  • • Equity Multiplier: 1.12x
  • Recent ROE (-71.26%) is below the historical average (-53.27%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2018 -89.10% -69.86% 0.88x 1.44x AU$-1.91 Million
2019 -39.93% -139.37% 0.26x 1.12x AU$-4.61 Million
2020 -85.23% -249.35% 0.31x 1.12x AU$-7.77 Million
2021 -50.41% -319.77% 0.14x 1.12x AU$-12.25 Million
2022 -25.75% -367.78% 0.06x 1.08x AU$-32.98 Million
2023 -35.57% -251.03% 0.13x 1.11x AU$-31.52 Million
2024 -28.93% -367.83% 0.07x 1.06x AU$-56.95 Million
2025 -71.26% -679.45% 0.09x 1.12x AU$-73.32 Million

Industry Comparison

This section compares Clarity Pharmaceuticals Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $11,537,405
  • Average return on equity (ROE) among peers: -124.60%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Clarity Pharmaceuticals Ltd (CU6) AU$90.23 Million -89.10% 0.12x $763.38 Million
Adalta Ltd (1AD) $172.82K -722.64% 1.66x $8.12 Million
Algorae Pharmaceuticals Ltd (1AI) $8.43 Million -80.40% 0.15x $20.04 Million
ACRUX Ltd (ACR) $43.92 Million -0.55% 0.08x $3.49 Million
Actinogen Medical Ltd (ACW) $21.74 Million -43.69% 0.07x $103.45 Million
Argenica Therapeutics Ltd (AGN) $8.31 Million -49.24% 0.09x $15.45 Million
Arovella Therapeutics Ltd (ALA) $19.30 Million -17.45% 0.18x $66.62 Million
Anatara Lifesciences Ltd (ANR) $5.92 Million -48.49% 0.08x $1.57 Million
Alterity Therapeutics Ltd (ATH) $-80.67K 0.00% 0.00x $80.80 Million
Amplia Therapeutics Ltd (ATX) $6.07 Million -40.21% 0.29x $54.45 Million
Avecho Biotechnology Ltd (AVE) $1.59 Million -243.30% 0.02x $31.19 Million

About Clarity Pharmaceuticals Ltd

AU:CU6 Australia Biotechnology
Market Cap
$763.38 Million
AU$1.08 Billion AUD
Market Cap Rank
#10389 Global
#258 in Australia
Share Price
AU$2.90
Change (1 day)
+2.47%
52-Week Range
AU$1.90 - AU$5.70
All Time High
AU$8.79
Categories
Companies in Australia Biotechnology
About

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic ra… Read more